Human immunodeficiency virus (HIV) in developing countries

REFERENCES

• Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M. & Berger, E. A. (1996). CC CKR5: a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science, 272, 1955–1958.
   PubMed Web of Science ®Google Scholar
• Allen, S., Meinzen-Derr, J., Kautzman, M., Zulu, I., Trask, S., Fideli, U., Musonda, R, Kasolo, F., Gao, F. & Haworth, A. (2003). Sexual behaviour of HIV discordant couples after HIV counselling and testing. AIDS, 17, 733–740.
   PubMed Web of Science ®Google Scholar
• Anglaret, X., Chéne, G., Attia, A., Toure, S., Lafont, S., Combe, P., Manlan, K., N'Dri-Yoman, T. & Salamon, R (1999). Early chemopro-phylaxis with trimethoprim—sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet, 353, 1463-1468.
   Google Scholar
• Anglaret, X., Messou, E., Ouassa, T., Toure, S., Dakoury-Dogbo, N., Combe, P., Mahassadi, A., Seyler, C., N'Dri-Yoman, T., Salamon, R. & ANRS 1203 Study Group (2003). Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS, 17, 575-584.
   Google Scholar
• Anon. (2001). Declaration of Commitment on HIVIAIDS: Global Crisis - Global Action. New York, NY: United Nations.
   Google Scholar
• Anon. (2002). Estimating the Size of Populations at Risk for HIV: Issues and Methods, a Joint UNAIDSI IMPACTIFHI Workshop: Report and Conclusions. Research Triangle Park, NC: Family Health International.
   Google Scholar
• Anon. (2004). AIDS in Asia: Face the Facts. Bangkok: Monitoring the AIDS Pandemic (MAP).
   Google Scholar
• Anon. (2005a). AIDS Epidemic Update. Geneva: Joint United Nations Programme on HIV/AIDS.
   Google Scholar
• Anon. (2005b). Intensifying HIV Prevention. Geneva: Joint United Nations Programme on HIV/AIDS.
   Google Scholar
• Anon. (2005c). Guidelines on Estimating the Size of Populations at Risk for and Infected with HIV. Jakarta: Directorate General of Communicable Disease Control and Environmental Health.
   Google Scholar
• Anon. (2006). 2005: year in review. Vax, 4, unnumbered.
   Google Scholar
• Anzala, O. A., Ball, T. B., Rostron, T., O'Brien, S. J., Plummer, F. A., Rowland-Jones, S. L. & University of Nairobi Collaboration for HIV Research (1998). CCR2-641 allele and genotype association with delayed AIDS progression in African women. Lancet, 351, 1632–1633.
   Google Scholar
• Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R & Puren, A. (2005). Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Medicine, 2, e298.
   Google Scholar
• Bass, E. (2005). The two sides of PEPFAR in Uganda. Lancet, 365, 2077–2078.
   PubMed Web of Science ®Google Scholar
• Bayer, R. (1991). Public health policy and the AIDS epidemic. An end to HIV exceptionalism? New England Journal of Medicine, 324,1500–1504.
   PubMed Web of Science ®Google Scholar
• Blower, S., Bodine, E., Kahn, J. & McFarland, W. (2005). The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS, 19, 1–14.
   PubMed Web of Science ®Google Scholar
• Boerma, J. T., Ghys, P. & Walker, N. (2003). HIV estimates from national population-based surveys as a new gold standard. Lancet, 362, 1929–1931.
   PubMed Web of Science ®Google Scholar
• Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. & Oldstone, M. B. (1994). Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with con-trol of viremia in primary human immunodeficiency virus type 1 infection. Journal of Virology, 68, 6103-6110.
   Google Scholar
• Cao, H., Kaleebu, P., Hom, D., Flores, J., Agrawal, D., Jones, N., Serwanga, J., Okello, M., Walker, C.,
   Google Scholar
• Sheppard, H., El-Habib, R., Klein, M., Mbidde, E., Mugyenyi, P., Walker, B., Ellner, J., Mugerwa, R. & The HIV Network for Prevention Trials (2003). Immunogenicity of a recombinant human immuno-deficiency virus (HIV) canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. Journal of Infectious Diseases, 187, 887-895.
   Google Scholar
• Cocchi, F., de Vico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C. & Lusso, P. (1995). Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV suppressive factors produced by CD4 + T cells. Science, 270, 1811–1815.
   PubMed Web of Science ®Google Scholar
• Coetzee, D., Hildebrand, K., Boulle, A., Maartens, G., Louis, F., Labatala, V., Reuter, H., Ntwana, N. & Goemaere, E. (2004). Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS, 18, 887–895.
   PubMed Web of Science ®Google Scholar
• Collier, A. C., Coombs, R W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C. & Corey, L. (1996). Treatment of human immuno-deficiency virus infection with saquinavir, zidovu-dine, and zalcitabine. AIDS Clinical Trials Group. New England Journal of Medicine, 334, 1011–1017.
   PubMed Web of Science ®Google Scholar
• Corbett, E. L., Churchyard, G. J., Charalambos, S., Samb, B., Moloi, V., Clayton, T. C., Grant, A. D., Murray, J., Hayes, R. J. & De Cock, K. M. (2002). Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clinical Infectious Diseases, 34,1251–1258.
   PubMed Web of Science ®Google Scholar
• Dalgleish, A. G., Beverly, P. C. L., Clapham, P. R., Crawford, D. H., Greaves, M. F. & Weiss, R. (1984). CD4(T4) antigen is an essential component of the receptor for AIDS retrovirus. Nature, 312, 763-767.
   Google Scholar
• De Cock, K. M., Mbori-Ngacha, D. & Marum, E. (2002). Shadow on the continent: public health and HIV/AIDS in Africa in the 21st Century. Lancet, 360, 67–72.
   Google Scholar
• De Cock, K. M., Marum, E. & Mbori-Ngacha, D. (2003). A serostatus-based approach to HIV/AIDS prevention and care in Africa. Lancet, 362, 1847–1849.
   PubMed Web of Science ®Google Scholar
• De Cock, K. M., Bunnell, R. & Mermin, J. (2006). Unfinished business - expanding HIV testing in developing countries. New England Journal of Medicine, 354,440–442.
   PubMed Web of Science ®Google Scholar
• Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W., Allikmets, R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomperts, E., Donfield, S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C., Detels, R. & O'Brien, S. J. (1996). Genetic restriction of HIV-1 infection and progres-sion to AIDS by a common deletion allele of the chemokine receptor 5 structural gene. Science, 273, 1856–1962.
   PubMed Web of Science ®Google Scholar
• Diaz, T., De Cock, K., Brown, T., Ghys, P. D. & Boerma, J. T. (2005a). New strategies for HIV surveillance in resource-constrained settings: an overview. AIDS, 19 (Suppl. 2), S1-S8.
   Google Scholar
• Diaz, T., Loth, G., Whitworth, J. & Sutherland, D. (2005b). Surveillance methods to monitor the impact of HIV therapy programmes in resource-constrained countries. AIDS, 19 (Suppl. 2), S31–S37.
   Google Scholar
• Diomande, F. V., Bissagnene, E., Nkengasong, J. N., Maurice, C., Monga, B., Laga, M. & Nolan, M. L. (2003). The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: empirical data from Ciite d'Ivoire's Drug Access Initiative. AIDS, 17 (Suppl. 3), S87-S93.
   Google Scholar
• Dowling, W. E., Kim, B., Mason, C. J., Wasunna, K. M., Alam, U., Elson, L., Birx, D. L., Robb, M. L., McCutchan, F. E. & Carr, J. K. (2002). Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recom-binants. AIDS, 16, 1809–1820.
   PubMed Web of Science ®Google Scholar
• Feng, Y., Brider, C. C., Kennedy, P. E. & Berger, E. A. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 272,872-877.
   Google Scholar
• Ferrari, G., Humphrey, W., McElrath, M. J., Excler, J. L., Duliege, A. M., Clements, M. L., Corey, L. C., Bolognesi, D. P. & Weinhold, K. J. (1997). Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proceedings of the National Academy of Sciences of the United States of America, 94, 1396–1401.
   PubMed Web of Science ®Google Scholar
• Fleming, D. T. & Wasserheit, J. N. (1999). From epidemiological synergy to public health policy and practice: the contribution of other sexually trans-mitted diseases to sexual transmission of HIV infection. Sexually Transmitted Infections, 75,3–17.
   PubMed Web of Science ®Google Scholar
• Flynn, N. M., Forthal, D. N., Harro, C. D., Judson, F. N., Mayer, K. H. & Para, MF; The rgp120 HIV Vaccine Study Group (2005). Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. Journal of Infectious Diseases, 191, 654-665.
   Google Scholar
• Freeman, E. E., Weiss, H. A., Glynn, J. R., Cross, P. L., Whitworth, J. A. & Hayes, R. J. (2006). Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS, 20, 73–83.
   PubMed Web of Science ®Google Scholar
• French, N., Mujugira, A., Nakiyingi, J., Mulder, D., Janoff, E. N. & Gilks, C. F. (1999). Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. Journal of Acquired Immune Deficiency Syndromes, 22, 509–516.
   PubMed Web of Science ®Google Scholar
• French, N., Nakiyingi, J., Carpenter, L. M., Lugada, E., Watera, C., Moi, K., Moore, M., Antvelink, D., Mulder, D., Janoff, E. N., Whitworth, J. & Gilks, C. F. (2000). 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet, 355,2106–2111.
   PubMed Web of Science ®Google Scholar
• French, N., Nakiyingi, J., Lugada, E., Watera, C., Whitworth, J. A. G. & Gilks, C. F. (2001). Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS, 15, 899–906.
   PubMed Web of Science ®Google Scholar
• French, N., Gray, K., Watera, C., Nakiyingi, J., Lugada, E., Moore, M., Lalloo, D., Whitworth, J. A. G. & Gilks, C. F. (2002). Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS, 16, 1031–1038.
   PubMed Web of Science ®Google Scholar
• Frieden, T. R., Das-Douglas, M., Kellerman, S. E. & Henning, K. J. (2005). Applying public health principles to the HIV epidemic. New England Journal of Medicine, 353, 2397-2402.
   Google Scholar
• Garcia-Calleja, J. M., Zaniewski, E., Ghys, P. D., Stanecki, K. & Walker, N. (2004). A global analysis of trends in the quality of HIV sero-surveillance. Sexually Transmitted Infections, 80 (Suppl. 1), 125–130.
   Google Scholar
• Gilks, C. F., Ojoo, S. A., Ojoo, J. C., Brindle, R. J., Paul, J., Batchelor, B. I., Kimari, J. N., Newnham, R., Bwayo, J., Plummer, F. A. & Warrell, D. A. (1996). Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet, 347, 718-723.
   Google Scholar
• Girardi, E., Sabin, C. A., d'Arminio Monforte, A., Hogg, B., Phillips, A. N., Gill, M. J., Dabis, F., Reiss, P., Kirk, O., Bernasconi, E., Grabar, S., Justice, A., Staszewski, S., Fatkenheuer, G. & Sterne, J. A. (2005). Incidence of tuberculosis among HIV-infected patients receiving highly active antire-troviral therapy in Europe and North America. Clinical Infectious Diseases, 41, 1772–1782.
   Google Scholar
• Grant, A. D., Djomand, G. & De Cock, K. M. (1997). Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS, 11, s43–s54.
   PubMedGoogle Scholar
• Grant, A. D., Kaplan, J. E. & De Cock, K. M. (2001). Preventing opportunistic infections among human immunodeficiency virus-infected adults in African countries. American Journal of Tropical Medicine and Hygiene, 65, 810–821.
   PubMed Web of Science ®Google Scholar
• Gray, R. H., Wawer, M. J., Brookmeyer, R., Sewankambo, N. K., Serwadda, D., Wabwire-Mangen, F., Lutalo, T., Li, X., van Cott, T. & Quinn, T. C. (2001). Probability of HIV-1 transmis-sion per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet, 357, 1149.
   PubMed Web of Science ®Google Scholar
• Gray, R. H., Li, X., Wawer, M. J., Gange, S. J., Serwadda, D., Sewankambo, N. K., Moore, R., Wabwire-Mangen, F., Lutalo, T. & Quinn, T. C. (2003). Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS, 17, 1941–1951 .
   PubMed Web of Science ®Google Scholar
• Gregson, S., Nyamukapa, C. A., Garnett, G. P., Mason, P. R., Zhuwau, T., Camel, M., Chandiwana, S. K. & Anderson, R. M. (2002). Sexual mixing patterns and sex-differentials in teen-age exposure to HIV infection in rural Zimbabwe. Lancet, 359, 1896–1903.
   PubMed Web of Science ®Google Scholar
• Gregson, S., Garnett, G. P., Nyamukapa, C. A., Hallett, T. B., Lewis, J. J., Mason, P. R., Chandiwana, S. K. & Anderson, R. M. (2006). HIV decline associated with behavior change in eastern Zimbabwe. Science, 311, 620–621.
   PubMedGoogle Scholar
• Grimwade, K. & Gilks, C. (2001). Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries. Current Opinion in Infectious Diseases, 14, 507–512.
   PubMed Web of Science ®Google Scholar
• Grosskurth, H., Mosha, F., Todd, J., Mwijarubi, E., Klokke, A., Senkoro, K., Mayaud, P., Changalucha, J., Nicholl, A., Ka-Gina, G., Newell, J., Mugeye, K., Mabey, D. & Hayes, R. (1995). Impact of improved treatment of sexually trans-mitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet, 346, 530–536.
   PubMed Web of Science ®Google Scholar
• Guadalupe, M., Reay, E., Sankaran, S., Prindiville, T., Flamm, J., McNeil, A. & Dandekar, S. (2003). Severe CD4 T cells depletion in the gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. Journal of Virology, 77, 11,708-11,717.
   Google Scholar
• Guay, L. A., Musoke, P., Fleming, T., Bagenda, D., Allen, M., Nakabiito, C., Sherman, J., Bakaki, P., Ducar, C., Deseyve, M., Emel, L., Mirochnick, M., Fowler, M. G., Mofenson, L., Miotti, P., Dransfield, K., Bray, D., Mmiro, F. & Jackson, J. B. (1999). Intrapartum and neonatal single-dose nevir-apine compared to zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet, 354, 795–802.
   PubMed Web of Science ®Google Scholar
• Hahn, B. H., Shaw, G. M., De Cock, K. M. & Sharp, P. M. (2000). AIDS as a zoonosis: scientific and public health implications. Science, 287, 607–614.
   PubMed Web of Science ®Google Scholar
• Heffernan, R. T., Barrett, N. L., Gallagher, K. M., Hadler, J. L., Harrison, L. H., Reingold, A. L., Khoshnood, K., Holford, T. R. & Schuchat, A. (2005). Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. Journal of Infectious Diseases, 191, 2038–2045.
   PubMed Web of Science ®Google Scholar
• Hoelscher, M., Dowling, W. E., Sanders-Buell, E., Carr, J. K., Harris, M. E., Thomschke, A., Robb, M. L., Birx, D. L. & McCutchan, F. E. (2002). Detection of HIV-1 subtypes, recombinants, and dual infections in East Africa by a multi-region hybridization assay. AIDS, 16, 2055-2064.
   Google Scholar
• Hogan, D. R., Baltussen, R, Hayashi, C., Lauer, J. A. & Salomon, J. A. (2005). Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. Lancet, 331, 1431–1435.
   Google Scholar
• Janssen, R S., Satten, G. A., Stramer, S. L., Rawal, B. D., O'Brien, T. R., Weiblen, B. J., Hecht, F. M., Jack, N., Cleghorn, F. R, Kahn, J. O., Chesney, M. A. & Busch, M. P. (1998). New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. Journal of the American Medical Association, 280, 42-48.
   Google Scholar
• Janssen, R. S., Holtgrave, D. R, Valdiserri, R. O., Shepherd, M., Gayle, H. D. & De Cock, K. M. (2001). The serostatus approach to fighting the HIV epidemic: prevention strategies for infected indivi-duals. American Journal of Public Health, 91, 1019-1024 .
   Google Scholar
• Kantor, R, Katzenstein, D. A., Efron, B., Carvalho, A. P., Wynhoven, B., Cane, P., Clarke, J., Sirivichayakul, S., Soares, M. A., Snoeck, J., Pillay, C., Rudich, H., Rodrigues, R., Holguin, A., Ariyoshi, K., Bouzas, M. B., Cahn, P., Sugiura, W., Soriano, V., Brigido, L. F., Grossman, Z., Morris, L., Vandamme, A. M., Tanuri, A., Phanuphak, P., Weber, J. N., Pillay, D., Harrigan, P. R., Camacho, R., Schapiro, J. M. & Shafer, R W. (2005). Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase geno-type: results of a global collaboration. PLoS Medicine, 2, e112.
   PubMed Web of Science ®Google Scholar
• Karnasuta, C., Paris, R. M., Cox, J. H., Nitayaphan, S., Pitisuttithum, P., Thongcharoen, P., Brown, A. E., Gurunathan, S., Tartaglia, J., Heyward, W. L., McNeil, J. G., Birx, D. L., de Souza, M. S. & TAVEG Thai AIDS Vaccine Evaluation Group, Thailand (2005). Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime—boost HIV-1 vaccine trial in Thailand. Vaccine, 23, 2522-2529.
   Google Scholar
• Kaslow, R. A., Carrington, M., Apple, R., Park, L., Munoz, A., Saah, A. J., Goedert, J. J., Winkler, C., O'Brien, S. J., Rinaldo, C., Detels, R., Blatmer, W., Phair, J., Erlich, H. & Mann, D. L. (1996). Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Medicine, 2, 405-411
   Google Scholar
• Kassa, E., Rinke de Wit, T. F., Hailu, E., Girma, M., Messele, T., Mariam, H. G., Yohannes, S., Jurriaans, S., Yeneneh, H., Coutinho, R.A. & Fontanet, A. L. (1999). Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. AIDS, 13, 381-389.
   Google Scholar
• Keele, B. F., van Heuverswyn, F., Li, Y., Bailes, E., Takehisa. J., Santiago, M. L., Bibollet-Ruche, F., Chen, Y., Wain, L. V., Liegeois, F., Loul, S., Mpoudi Ngole, E., Bienvenue, Y., Delaporte, E., Brookfield, J. F. Y., Sharp, P. M., Shaw, G. M., Peeters, M. & Hahn, B. H. (2006). Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science, in press.
   Google Scholar
• Khoo, S., Back, D. & Winstanley, P. (2005). The potential for interactions between antimalarial and antiretroviral drugs. AIDS, 19, 995–1005.
   PubMed Web of Science ®Google Scholar
• Kim, J. Y. & Gilks, C. (2005). Scaling up treatment - why we can't wait. New England Journal of Medicine, 352, 2392–2394.
   Google Scholar
• Klatzmann, D., Campagne, E., Chamaret, S., Gurest, J., Guetard, D., Hercend, T., Gluckman, J. C. & Montagnier, L. T. (1984). Lymphocyte T4 behaves as the receptor for human retrovirus LAV. Nature, 312, 767–771.
   PubMed Web of Science ®Google Scholar
• Klausner, R. D., Fauci, A. S., Corey, L., Nabel, G. J., Gayle, H., Berkley, S., Haynes, B. F., Baltimore, D., Collins, C., Douglas, R. G., Esparza, J., Francis, D. P., Ganguly, N. K., Gerberding, J. L., Johnston, M. I., Kazatchkine, M. D., McMichael, A. J., Makgoba, M. W., Pantaleo, G., Piot, P., Shao, Y., Trarnont, E., Varmus, H. & Wasserheit, J. N. (2003). The need for a global HIV/AIDS vaccine enterprise. Science, 300, 2036–2039.
   PubMed Web of Science ®Google Scholar
• Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C. & Ho, D. D. (1994). Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. Journal of Virology, 68, 4650–4655.
   PubMed Web of Science ®Google Scholar
• Kreiss, J., Ngugi, E., Holmes, K., Ndinya-Achola, J., Waiyaki, P., Roberts, P. L., Ruminjo, I., Sajabi, R., Kimata, J., Fleming, T. R., Anzala, A., Holton, D. & Plummer, F. (1992). Efficacy of nonoxynol 9 contra-ceptive sponge use in preventing heterosexual acqui-sition of HIV in Nairobi prostitutes. Journal of the American Medical Association, 268, 477-482.
   Google Scholar
• Kumar, R, Jha, P., Arora, P., Mony, P., Bhatia, P., Millson, P., Dhingra, D., Bhattacharya, M., Remis, R. S. & Nagelkerke, N., for the International Studies of HIV/AIDS (ISHA) Investigators (2006). Trends in HIV-1 in young adults in south India from 2000 to 2004: a prevalence study. Lancet, 367, 1164-1172.
   Google Scholar
• Lawn, S. D., Badri, M. & Wood, R. (2005a). Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS, 19, 2109–2116.
   PubMed Web of Science ®Google Scholar
• Lawn, S. D., Myer, L., Orrell, C., Bekker, L. G. & Wood, R. (2005b). Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS, 19, 2141–2148.
   PubMed Web of Science ®Google Scholar
• Lehner, T. & Anton, P. A. (2002). Mucosal immunity and vaccination against HIV. AIDS, 16 (Suppl. 4), S125-S132.
   Google Scholar
• Levy, J. A., Scott, I. & Mackewicz, C. (2003). Protection from HIV/AIDS: the importance of innate immunity. Clinical Immunology, 108, 167–174.
   PubMed Web of Science ®Google Scholar
• Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E.,
   Google Scholar
• Stuhlmann, H., Koup, R. A. & Landau, N. R. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86, 367–377.
   PubMed Web of Science ®Google Scholar
• Mbulaiteye, S. M., Mahe, C., Whitworth, J. A. G., Ruberwantari, A., Nakiyingi, J. S., Ojwiya, A. & Kamali, A. (2002). Declining HIV-1 incidence and associated prevalence over 10-years in a rural population in south-west Uganda: a cohort study. Lancet, 360, 41–46.
   PubMed Web of Science ®Google Scholar
• Mehandru, S., Poles, M. A., Tenner-Racz, K., Horowitz, A., Hurley, A., Hogan, C., Boden, D., Racz, P. & Markowitz, M. (2004). Primary HIV-1 infection is associated with preferential depletion of CD4 T lymphocytes from effector sites in the gastrointestinal tract. Journal of Experimental Medicine, 200, 761–770.
   PubMed Web of Science ®Google Scholar
• Migueles, S. A., Sabbaghian, M. S., Shupert, W. L., Bettinotti, M. P., Marincola, F. M., Martino, L., Hallahan, C. W., Selig, S. M., Schwartz, D., Sullivan, J. & Connors, M. (2000). HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-linfected long term nonpro-gressors. Proceedings of the National Academy of Sciences of the United States of America, 97, 2709–2714 .
   PubMed Web of Science ®Google Scholar
• Mills, E., Rachlis, B., Wu, P., Wong, W., Wilson, K. & Singh, S. (2005). Media reporting of tenofovir trials in Cambodia and Cameroon. BMC International Health and Human Rights, 5, 6.
   PubMedGoogle Scholar
• Morgan, D. & Whitworth, J. (2001). The natural history of HIV-1 infection in Africa. Nature Medicine, 7, 143–145.
   PubMed Web of Science ®Google Scholar
• Morgan, D., Maude, G. H., Malamba, S. S., Okongo, M. J., Wagner, H. U., Mulder, D. W. & Whitworth, J. A. (1997). HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet, 350, 245–250.
   PubMed Web of Science ®Google Scholar
• Morris, L., Martin, D. J., Bredell, H., Nyoka, S. N., Sacks, L., Pendle, S., Page-Shipp, L., Karp, C. L., Sterling, T. R., Quinn, T. C. & Chaisson, R E. (2003). Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. Journal of Infectious Diseases, 187, 1967–1971.
   PubMed Web of Science ®Google Scholar
• Mugerwa, R. D., Kaleebu, P., Mugyenyi, P., Katongole-Mbidde, E., Hom, D. L., Byaruhanga, R., Salata, R. A., Ellner, J. J. & The HIV-1 Vaccine Trial Group (2002). First trial of the HIV-1 vaccine in Africa: Ugandan experience. British Medical Journal, 324, 226-229.
   Google Scholar
• Mugisha, E., Nakwagala, F., Konde, C., Johnson, B., Nanvubya, A., Birungi, J., Muluubya, A., Kiwanuka, P., Nielsen, L., Schmidt, C., Fast, P., Thiry, G. & Kaleebu, P. (2006). Community based volunteer recruitment and community involvement: experiences and lessons learnt from the second HIV vaccine trial in Uganda. Journal of Acquired Immune Deficiency Syndromes, in press.
   Google Scholar
• Mugyenyi, P. N. (2002). HIV vaccines: the Uganda experience. Vaccine, 20, 1905–1908.
   PubMed Web of Science ®Google Scholar
• Mukherjee, J. S., Farmer, P. E., Niyizonkiza, D., McCorkle, L., Vanderwarker, C., Teixeira, P. & Kim, J. Y. (2003). Tackling HIV in resource poor countries. British Medical Journal, 327,1104–1106.
   PubMed Web of Science ®Google Scholar
• Orroth, K. K., Korenromp, E. L., White, R. G., Gayvole, A., Gray, R H., Muhangi, L., Sewankambo, N. K., Quigley, M., Wawer, M. J., Whitworth, J. A. G., Grosskurth, H., Habbema, J. D. F. & Hayes, R J. (2003). Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV preven-tion trial outcomes. AIDS, 17,2653–2660.
   PubMed Web of Science ®Google Scholar
• Parekh, B. S., Kennedy, M. S., Dobbs, T., Pau, C. P., Byers, R., Green, T., Hu, D. J., Vanichseni, S., Young, N. L., Choopanya, K., Mastro, T. D. & McDougal, J. S. (2002). Quantitative detection of increasing HIV type 1 antibodies after seroconver-sion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Research and Human Retroviruses, 18, 295–307.
   PubMed Web of Science ®Google Scholar
• Parkhurst, J. O. (2002). The Ugandan success story? Evidence and claims of HIV-1 prevention. Lancet, 360, 78-80.
   Google Scholar
• Peeters, M., Toure-Kane, C. & Nkengasong, J. N. (2003). Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS, 17, 2547–2560.
   PubMed Web of Science ®Google Scholar
• Pilcher, C. D., Tien, H. C., Eron J. J. Jr, Vemazza, P. L., Leu, S. Y., Stewart, P. W., Goh, L. E. & Cohen, M. S., for the Quest Study and the Duke-UNC-Emory Acute HIV Consortium (2004). Brief but efficient: acute HIV infection and the sexual transmission of HIV. Journal of Infectious Diseases, 189, 1785–1792.
   Google Scholar
• Pisani, E., Garnett, G. P., Grassly, N. C., Brown, T., Stover, J., Hankins, C., Walker, N. & Ghys, P. D. (2003). Back to basics in HIV prevention: focus on exposure. British Medical Journal, 326, 1384–1387.
   PubMed Web of Science ®Google Scholar
• Pitcher, C. J., Quitmer, C., Peterson, D. M., Connors, M., Koup, R A., Maino, V. C. & Picker, L. J. (1999). HIV-1 specific CD4T cells aredetectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppres-sion. Nature Medicine, 5,518–525.
   PubMed Web of Science ®Google Scholar
• Quigley, M. A., Mwinga, A., Hosp, M., Lisse, I., Fuchs, D., Porter, J. D. H. & Godfrey-Faussett, P. (2001). Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS, 15, 215–22.
   PubMed Web of Science ®Google Scholar
• Richard, N., Juntilla, M., Abraha, A., Demers, K., Paxinos, E., Galovich, J., Petropoulos, C., Whalen, C. C., Kyeyune, F., Atwine, D., Kityo, C., Mugyenyi, P. & Arts, E. J. (2004). High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodefi-ciency virus type 1. AIDS Research and Human Retroviruses, 20, 355-364.
   Google Scholar
• Roddy, R. E., Zekeng, L., Ryan, K. A., Tamoufe, U., Weir, S. S. & Wong, E. L. (1998). A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. New England Journal of Medicine, 339, 504–510.
   PubMed Web of Science ®Google Scholar
• Rosenberg, E. S., Altfeld, M., Poon, S. H., Phillips, M. N., Wilkes, B. M., Eldridge, R. L., Robbins, G. K., D'Aquila, R. T., Goulder, P. J. & Walker, B. D. (2000). Immune control of HIV-1 after early treatment of acute infection. Nature, 407, 523–526.
   PubMed Web of Science ®Google Scholar
• Salomon, J. A., Hogan, D. R., Stover, J., Stanecki, K. A., Walker, N., Ghys, P. D. & Schwartlander, B. (2005). Integrating HIV prevention and treatment: from slogans to impact. PLoS Medicine, 2, el 6.
   Google Scholar
• Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C. M., Saragosti, S., Lapoumemulie, C., Cognaux, J., Forceille, C., Muyldermans, G., Verhofstede, C., Burtonboy, G., Georges, M., Imai, T., Rana, S., Yi, Y., Smyth, R. J., Collman, R. G., Doms, R. W., Vassart, G. & Parmentier, M. (1996). Resistance to HIV-1 infec-tion in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 382, 722–725.
   PubMed Web of Science ®Google Scholar
• Seyler, C., Anglaret, X., Dakoury-Dogbo, N., Messou, E., Toure, S., Danel, C., Diakite, N., Daudie, A., Inwoley, A., Maurice, C., Tonwe-Gold, B., Rouet, F., N'Dri-Yoman, T. & Salamon, R. (2003). Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antiviral Therapy, 8, 385-393.
   Google Scholar
• Shelton, J. D., Halperin, D. T., Nantulya, V., Potts, M. & Gayle, H. D. (2004). Parmer reduction is crucial for balanced ‘ABC’ approach to HIV prevention. British Medical Journal, 328, 891–894.
   PubMed Web of Science ®Google Scholar
• Shelton, J. D., Halperin, D. T. & Wilson, D. (2006). Has global HIV incidence peaked? Lancet, 367, 1120–1121.
   PubMed Web of Science ®Google Scholar
• Speelmon, E. C. D., Livingston-Rosanoff, D., Li, S. S., Vu, Q., Bui, J., Geraghty, D. E., Zhao, L. P. & McElrath, M. J. (2006). Genetic association of the antiviral restriction factor TRINI5alpha with human immunodeficiency virus type 1 infection. Journal of Virology, 80, 2463-2471.
   Google Scholar
• Stolte, I. G., Dukers, N. H. T. M, de Wit, J. B. F., Fennema, H. & Coutinho, R. A. (2002). A summary report from Amsterdam: increase in sexually trans-mitted diseases and risky sexual behaviour among homosexual men in relation to the introduction of new anti-HIV drugs. Eurosurveillance, 7,19-22.
   Google Scholar
• Stover, J., Walker, N., Garnett, G. P., Salomon, J. A., Staneki, K. A., Ghys, P. D., Grassly, N. C., Anderson, R. M. & Schwartlander, B. (2002). Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet, 360, 73–77.
   PubMed Web of Science ®Google Scholar
• Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiegne-Traore, V., Uaheowitchai, C., Karim, S. S., Masse, B., Perriens, J. & Laga, M., on behalf of the COL-1492 Study Group (2002). Effectiveness of COL-1492, a nonoxyno1-9 vaginal gel, on HIV-1 transmis-sion in female sex workers: a randomized controlled trial. Lancet, 360, 971-977.
   Google Scholar
• Van Damme, W., Kober, K. & Laga, M. (2006). The real challenges for scaling up ART in sub-Saharan Africa. AIDS, 20, 653–656.
   PubMed Web of Science ®Google Scholar
• Van Oosterhout, J. J., Laufer, M. K., Graham, S. M., Thumba, F., Perez, M. A., Chimbiya, N., Wilson, L., Chagomerana, M., Molyneux, M. E., Zijlstra, E. E., Taylor, T. E. & Plowe, C. V. (2005). A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. Journal of Acquired Immune Deficiency Syndromes, 39, 626–631.
   PubMed Web of Science ®Google Scholar
• Wald, A. & Link, K. (2002). Risk of human immuno-deficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. Journal of Infectious Diseases, 185, 45-52.
   Google Scholar
• Wasserheit, J. N. (1992). Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sexually Transmitted Diseases, 19, 61–77.
   PubMed Web of Science ®Google Scholar
• Watera, C., Whitworth, J. A. G., Muwonge, R., Todd, J., Nakiyingi, J., Brink, A., Miiro, G., Antvelink, L., Kamali, A., French, N. & Mermin, J. (2006). Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. Journal of Acquired Immune Deficiency Syndromes, in press.
   Google Scholar
• Wawer, M. J., Serwadda, D., Li, X., Quinn, T. C., Sewankambo, N. K., Kiwanuka, N., Kigozi, G. & Gray, R. H. (2003). HIV-1 transmission per coital act, by stage of HIV Infection in the HIV+ index partner, in discordant couples, Rakai, Uganda. In 10th Conference on Retroviruses and Opportunistic Infections, abstract 40 (www.retroconference.org/2003/cd/Abstract/40.htm). Alexandria, VA: Foundation for Retrovirology and Human Health.
   Google Scholar
• Weber, J., Desai, K. & Darbyshire, J., on behalf of the Microbicide Development Programme. (2005). The development of vaginal microbicides for prevention of HIV transmission. PloS Medicine, 2, e142.
   Google Scholar
• Weidle, P. J., Malamba, S., Mwebaze, R., Sozi, C., Rukundo, G., Downing, R., Hanson, D., Ochola, D., Mugyenyi, P., Mermin, J., Samb, B. & Lackritz, E. (2002). Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet, 360, 34–40.
   PubMed Web of Science ®Google Scholar
• Whalen, C. C., Johnson, J. L., Okwera, A., Horn, D. L., Huebner, R, Mugyenyi, P., Mugerwa, R. D. & Ellner, J. J. (1997). A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. New England Journal of Medicine, 337,801-808.
   Google Scholar
• Wiktor, S. Z., Sassan-Morokro, M., Grant, A. D., Abouya, L., Karon, J. M., Maurice, C., Djomand, G., Ackah, A., Domoua, K., Kadio, A., Yapi, A., Combe, P., Tossou, O., Roels, T. H., Lackritz, E. M., Coulibaly, D., De Cock, K. M., Coulibaly, I. M. & Greenberg, A. E. (1999). Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, 0:Re d'Ivoire: a randomised controlled trial. Lancet, 353,1469-1475.
   Google Scholar
• World Health Organization (2000). Guidelines for Second Generation HIV Surveillance. Document WHO/CDS/EDC/2000.05. Geneva: WHO.
   Google Scholar
• World Health Organization (2002). Prevention of HIV in Infants and Young Children. Review of Evidence and WHO's Activities. Document WHO/HIV/2002.08. Geneva: WHO.
   Google Scholar
• World Health Organization (2004). Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Guidelines on Care, Treatment and Support for Women Living with HIVIAIDS and their Children in Resource-constrained Settings. Geneva: WHO.
   Google Scholar
• World Health Organization (2005a). ‘3 by 5’ Progress Report, June 2005. Geneva: WHO.
   Google Scholar
• World Health Organization (2005b). Progress on Global Access to HIV Antiretroviral Therapy: an Update on ‘3 by 5’. Geneva: WHO.
   Google Scholar
• World Health Organization (2006a). WHO Expert Consultation on Cotrimoxazole Prophylaxis in HIV Infection. Technical Report Series. Geneva: WHO.
   Google Scholar
• World Health Organization (2006b). Global Access to HIV Therapy Tripled in past Two Years, but Significant Challenges Remain. Geneva: WHO.
   Google Scholar
• Xu, H., Svarovskaia, E. S., Barr, R., Zhang, Y., Khan, M. A., Strebel, K. & Pathak, V. K. (2004). A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proceedings of the National Academy of Sciences of the United States of America, 101, 5652–5657.
   PubMed Web of Science ®Google Scholar
• Yirrell, D., Kaleebu, P., Mogan, D., Watera, C., Magambo, B., Lyagoba, F. & Whitworth, J. (2002). Inter- and intra-genic intersubtype HIV-1 recombi-nation in rural and semi-urban Uganda. AIDS, 16, 279–286.
   PubMed Web of Science ®Google Scholar
• Zachariah, R., Teck, R., Ascurra, O., Humblet, P. & Harries, A. D. (2006). Targeting CD4 testing to a clinical subgroup of patients could limit unnecessary CD4 measurements, premature antiretroviral treat-ment and costs in Thyolo district, Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100,24-31.
   Google Scholar